You are viewing an incomplete version of our website. Please click to reload the website as full version.

Independent validation of first reproducibility initiative study

PALO ALTO, Calif. — DECEMBER 17, 2014— The Science Exchange independent validation service announced today the first successful replication study for the Reproducibility Initiative. The Reproducibility Initiative was launched in response to revelations from the pharmaceutical industry that more than 70% of published research findings cannot be reproduced, significantly impacting their ability to develop effective new therapies to treat disease. The Reproducibility Initiative solves the reproducibility problem by identifying and rewarding high quality reproducible research through independent validation of key experimental results.

The first study to be replicated is the 2011 PLOS Neglected Tropical Diseases paper "Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival". Replication experiments conducted by the Science Exchange facilities New York University Anti-Infectives Screening and Insectary Core Facility and the LifeTeine showed that the anti-leishmanial activities of BMAP-28 peptide in vitro could be independently reproduced. The replication study was published today in the PLOS ONE reproducibility collection and the data will be deposited in the Open Science Framework. Mendeley analytics will be used to track readership and citations of the original and replication studies to determine the impact on the field of replicating the study.

The first replication study was sponsored by antibodies-online, a partner of the Reproducibility Initiative. “Our contribution to the Reproducibility Initiative besides the sponsorship of the initially study is our investment in the Independent Validation Initiative”, says Dr. Andreas Kessell, co-founder of The program offers the possibility to provide independently generated data of commercially available research antibodies and ELISA kits to end customers ( )

Dr. W. Robert McMaster, the corresponding author of the original study expressed his support for the Reproducibility Initiative stating “I’m happy to have my results independently validated by the Reproducibility Initiative. This provides evidence that the anti-parasitic activity of BMAP-28 peptides is robust and worth pursuing as a potential therapeutic strategy for Leishmania, a disease that affects 20 million people worldwide.”

“I am very excited at the success of our first Reproducibility Initiative replication study,” said Dr. Elizabeth Iorns, CEO of Science Exchange and Director of the Reproducibility Initiative. “This study cost ~$2,000 to replicate, demonstrating how cost effective it can be to independently validate key experimental results from important studies. I hope this will provide an important example for how replication studies can be implemented as part of the research workflow to improve the confidence in novel results.”